Orris

Progrmatic management of Dr tb Full details for md exams

Programmatic management of Drug-Resistant TB (DR-TB): full exam-focused notes for MD
Below is a high-yield, structured answer you can reproduce in theory, long case, short notes, and viva.

1) Definition and classification

Drug-resistant TB = TB caused by Mycobacterium tuberculosis resistant to one or more anti-TB drugs.

Current WHO resistance categories

  • RR-TB: rifampicin-resistant TB (with/without resistance to other drugs)
  • MDR-TB: resistance to at least isoniazid + rifampicin
  • Pre-XDR-TB: MDR/RR-TB + resistance to any fluoroquinolone
  • XDR-TB: MDR/RR-TB + resistance to any fluoroquinolone + at least one additional Group A drug (e.g., bedaquiline or linezolid)
(Older XDR definitions may appear in older textbooks; mention “as per latest WHO definitions.”)

2) Programmatic framework (PMDT/NTEP approach)

Programmatic management means standardized, decentralized, patient-centered care under national TB control with:
  1. Early diagnosis using rapid molecular tests
  2. Universal DST-guided regimen selection
  3. Uninterrupted quality-assured drug supply
  4. Adherence support and monitoring
  5. Pharmacovigilance and adverse event management
  6. Infection control
  7. Nutritional, psychosocial, and socioeconomic support
  8. Recording, reporting, cohort analysis, contact management

3) Whom to suspect DR-TB (high-risk groups)

  • Previous TB treatment failure/relapse/lost-to-follow-up
  • Persistent sputum positivity after months of treatment
  • Contact of known DR-TB case
  • TB-HIV coinfection with poor response
  • Exposure in high DR-TB settings (prisons, mines, crowded institutions)
  • Non-conversion on first-line therapy

4) Diagnostic algorithm (exam-friendly)

Initial tests

  • NAAT (Xpert MTB/RIF or Ultra / Truenat) for all presumptive TB
  • Detects MTB + rifampicin resistance quickly

If rifampicin resistance detected

  • Label as RR-TB (presumptive DR-TB) and start DR-TB pathway
  • Send specimen for:
    • First-line and second-line LPA
    • Culture (liquid/solid) + phenotypic DST
    • Extended DST to guide individualized regimen

Baseline before starting regimen

  • CBC, LFT, RFT, electrolytes, blood sugar
  • ECG (especially if QT-prolonging drugs)
  • Thyroid profile if indicated
  • Viral markers/HIV test, pregnancy test (as relevant)
  • Chest X-ray; weight/BMI
  • Audiometry/vision/neuropathy assessment depending on drug plan

5) Principles of regimen design

  • Use at least 4 effective drugs (preferably oral all-oral regimens)
  • Prioritize drugs by WHO grouping and DST pattern
  • Never add a single drug to a failing regimen
  • Ensure weight-based dosing
  • Daily dosing, strict adherence, close follow-up
  • Individualize based on:
    • Resistance pattern
    • Prior exposure history
    • Disease severity/site
    • Comorbidities (HIV, liver, renal disease, pregnancy, diabetes)

6) Drug groups (high yield)

Group A (highest priority)

  • Levofloxacin/Moxifloxacin
  • Bedaquiline
  • Linezolid

Group B

  • Clofazimine
  • Cycloserine/Terizidone

Group C (add-ons as required)

  • Delamanid, Pyrazinamide, Ethambutol, Imipenem-cilastatin/Meropenem, Amikacin (selected situations), Ethionamide/Prothionamide, PAS etc.
    (Exact use depends on national guideline updates and DST.)

7) Common programmatic regimens (write conceptually)

A) Shorter all-oral bedaquiline-containing regimen (for eligible RR/MDR)

  • Duration around 9–11 months
  • Used when no resistance/contraindication to key drugs and patient meets eligibility

B) Longer individualized regimen

  • Usually 18–20 months (or guideline-updated duration)
  • For complicated resistance patterns, intolerance, extensive disease, ineligible for shorter regimen

C) Special resistant patterns

  • Pre-XDR/XDR-TB: build regimen with remaining active Group A/B/C drugs; expert committee decision
In exam: mention “follow latest national PMDT/NTEP and WHO update for exact composition.”

8) Monitoring during treatment

Bacteriological monitoring

  • Monthly sputum smear/culture initially, then per protocol
  • Culture conversion is key milestone

Clinical monitoring

  • Symptoms, weight gain, fever/cough improvement
  • Adherence checks each visit

Laboratory/targeted safety monitoring

  • CBC (linezolid myelosuppression)
  • LFT, RFT
  • ECG (QT prolongation with bedaquiline/clofazimine/delamanid)
  • Electrolytes (K, Mg, Ca if QT risk)
  • Neuropathy/optic symptoms (linezolid, cycloserine)
  • Psychiatric assessment (cycloserine)
  • Skin discoloration/GI effects (clofazimine)
  • Hearing/renal if injectables used

Outcome recording

  • Cured, treatment completed, failed, died, lost to follow-up, not evaluated
  • Cohort review for program performance

9) Adverse drug reactions (must-know viva points)

  • Bedaquiline: QT prolongation, hepatotoxicity
  • Linezolid: anemia, thrombocytopenia, peripheral/optic neuropathy, lactic acidosis
  • Fluoroquinolones: GI upset, tendinopathy, QT effects (moxifloxacin)
  • Clofazimine: skin pigmentation, GI intolerance, QT (additive)
  • Cycloserine: depression, psychosis, seizures
  • Ethionamide: GI upset, hypothyroidism, hepatotoxicity
  • Injectables (if used): ototoxicity, nephrotoxicity
Management principle: early detection, dose adjustment/temporary stoppage, substitution with effective alternative, never compromise core effective drug count.

10) PMDT support pillars (exam scoring section)

  • Decentralized DR-TB centers + nodal committees
  • Digital adherence technologies and treatment supporters
  • Nutritional support, travel support, social protection
  • Counseling for stigma, mental health, substance use
  • Contact tracing and TB preventive strategies where indicated
  • Airborne infection control:
    • Triage/cough etiquette/masks
    • Ventilation and spacing
    • HCW respiratory protection
  • Integrated HIV and diabetes care

11) Special situations

  • Pregnancy: avoid teratogenic drugs; individualized expert regimen
  • Children/adolescents: child-friendly formulations, close toxicity monitoring
  • HIV coinfection: early ART, drug-drug interaction checks
  • Extrapulmonary DR-TB: longer individualized treatment often needed
  • Severe unilateral destroyed lung/localized cavitary disease: consider adjunctive surgery in selected cases

12) Important exam flow answer (2-minute viva format)

“Programmatic management of DR-TB involves early molecular diagnosis of rifampicin resistance, universal DST, and prompt initiation of all-oral DST-guided regimens under national PMDT. Regimen design uses at least four effective drugs, prioritizing Group A agents like fluoroquinolone, bedaquiline, and linezolid, with Group B/C additions. Patients are monitored monthly for bacteriological conversion, adherence, and toxicity with ECG/lab surveillance and active pharmacovigilance. Management is patient-centered with nutritional, psychosocial, and financial support, strict infection control, contact management, and cohort-based outcome reporting.”

13) Common mistakes to mention (exam bonus)

  • Delayed DST or waiting for full culture before initiating DR pathway
  • Adding one drug to failing regimen
  • Poor ECG/toxicity monitoring with QT-prolonging combinations
  • Ignoring adherence and mental health factors
  • Inadequate documentation and follow-up after discharge/transfer
If you want, I can also give:
  1. Latest NTEP India regimen tables (drug-wise, phase-wise, weight-band doses)
  2. One-page last-minute revision sheet
  3. 20 viva questions with model answers on DR-TB PMDT
This is a shared conversation. Sign in to Orris to start your own chat.